At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed grade 4 astrocytoma (glioblastoma multiforme), including gliosarcoma, at primary diagnosis or recurrence
- ✓Progressive or recurrent disease
- ✓Measurable or evaluable disease by MRI or CT scan
- ✓ECOG performance status 0-2
- ✕Known HIV positivity
- ✕Uncontrolled infection
- ✕Known hypersensitivity to study drug components
- ✕Other active malignancy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Recurrent Glioblastoma
In Brief
A Phase 2 clinical trial evaluating vorinostat and conventional surgery for Adult Giant Cell Glioblastoma and 3 related conditions. Completed, enrolled 103 participants across 1 site.
Detailed Summary
This phase II trial is studying how well vorinostat works in treating patients with progressive or recurrent glioblastoma multiforme. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vorinostat before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may kill any remaining tumor cells.
Study Details
Timeline
Interventions
Given orally
Patients undergo surgery to remove tumor